WB result of SMAD7 Mouse mAb
Primary antibody: SMAD7 Mouse mAb at 1/5000 dilution
Lane 1: mouse kidney lysate 20 µg
Secondary antibody: Goat Anti-mouse IgG, (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 46 kDa
Observed MW: 52 kDa
This blot was developed with high sensitivity substrate
Product Details
Product Details
Product Specification
| Host | Mouse |
| Antigen | SMAD7 |
| Synonyms | SMAD family member 7; SMAD 7 Curated; hSMAD7; Mothers against decapentaplegic homolog 7 (MAD homolog 7; Mothers against DPP homolog 7); Mothers against decapentaplegic homolog 8 (MAD homolog 8; Mothers against DPP homolog 8); MADH7; MADH8; SMAD7 |
| Location | Cytoplasm, Nucleus |
| Accession | O15105 |
| Antibody Type | Mouse mAb |
| Isotype | IgG2a |
| Application | WB |
| Reactivity | Ms, Rt |
| Positive Sample | mouse kidney, rat kidney |
| Purification | Protein A |
| Concentration | 1 mg/ml |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 40% Glycerol, 0.05% BSA, 0.02% sodium azide |
| Stability & Storage | 12 months from date of receipt / reconstitution, -20 °C as supplied |
Dilution
| application | dilution | species |
| WB | 1:5000 | Ms, Rt |
Background
SMAD7 is a crucial inhibitory protein that acts as a negative regulator of the TGF-β signaling pathway. It maintains cellular homeostasis by binding to activated TGF-β receptors and preventing the phosphorylation of downstream SMAD proteins. Clinically, dysregulation of SMAD7 is closely associated with various pathologies, including colorectal cancer, fibrosis, and inflammatory bowel disease, making it a potential therapeutic target.
Picture
Picture
Western Blot
WB result of SMAD7 Mouse mAb
Primary antibody: SMAD7 Mouse mAb at 1/5000 dilution
Lane 1: rat kidney lysate 20 µg
Secondary antibody: Goat Anti-mouse IgG, (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 46 kDa
Observed MW: 52 kDa
This blot was developed with high sensitivity substrate
